<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623102</url>
  </required_header>
  <id_info>
    <org_study_id>WJP001</org_study_id>
    <nct_id>NCT01623102</nct_id>
  </id_info>
  <brief_title>Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer</brief_title>
  <official_title>An Open-label Randomized Phase II Trial of Gemcitabine and Cisplatin With or Without Bevacizumab in EGFR Wild-type Non-squamous Non-small-cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Cancer Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced non-small-cell lung cancer (NSCLC) patients without epidermal growth factor receptor&#xD;
      (EGFR) mutations show a poor prognosis. Gemcitabine combined with cisplatin chemotherapy is&#xD;
      an effective treatment measures for EGFR mutation-negative NSCLC patients, but the prognosis&#xD;
      remains poor. Chemotherapy combined with targeted monoclonal antibody treatment may be better&#xD;
      treatment options in these patients. Monoclonal antibodies, such as bevacizumab, can block&#xD;
      tumor growth in different ways. Bevacizumab blocks the ability of tumors to grow new blood&#xD;
      vessels and spread. It is not yet known whether cisplatin and gemcitabine is more effective&#xD;
      when given alone or with bevacizumab. This randomized trial studies how well giving cisplatin&#xD;
      and gemcitabine alone or in combination with Bevacizumab (Avastin) works in treating patients&#xD;
      with stage IIIB/IV non-squamous NSCLC without EGFR mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is the leading cause of cancer morbidity and mortality worldwide. The majority of&#xD;
      lung cancer is nonsquamous NSCLC. EGFR tyrosine kinase inhibitors (EGFR-TKI) is a effective&#xD;
      first-line treatment for EGFR mutations non-squamous NSCLC treatment. But those patients&#xD;
      without epidermal growth factor receptor (EGFR) mutations show a poorer prognosis.&#xD;
      Gemcitabine combined with cisplatin chemotherapy is an effective treatment measures for EGFR&#xD;
      mutation-negative NSCLC patients, but the prognosis remains poor. Chemotherapy combined with&#xD;
      targeted monoclonal antibody treatment may be better treatment options in these patients.&#xD;
      Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.&#xD;
      Bevacizumab blocks the ability of tumors to grow new blood vessels and spread. This&#xD;
      randomized trial studies how well giving cisplatin and gemcitabine alone or in combination&#xD;
      with Bevacizumab (Avastin) works in treating patients with stage IIIB/IV non-squamous NSCLC&#xD;
      without EGFR mutations. Accordingly, we have come to a scientific hypothesis that cisplatin&#xD;
      and gemcitabine combination with Bevacizumab might be a better treatment strategy for stage&#xD;
      IIIB/IV non-squamous NSCLC patients with EGFR wild-type. It can improve the PFS of stage&#xD;
      IIIB/IV non-squamous NSCLC patients with EGFR wild-type. The primary endpoint is disease-free&#xD;
      time to progression (PFS). The secondary study endpoint is objective response rate (ORR),&#xD;
      disease control rate (DCR), safety and quality of life (QOL). Through this study lay the&#xD;
      foundation for further exploration of the non-squamous NSCLC first-line treatment in patients&#xD;
      with EGFR wild-type strategy, and guide the rational application of bevacizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free time to progression</measure>
    <time_frame>6 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>6 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I: bevacizumab plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental arm receive cisplatin and gemcitabine combination with Bevacizumab. GP chemotherapy (gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) plus bevacizumab (7.5 mg/kg IV on D1 of every 21-day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive gemcitabine combined with cisplatin chemotherapy((gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) ) every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin and gemcitabine combination with Bevacizumab</intervention_name>
    <description>Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.</description>
    <arm_group_label>Arm I: bevacizumab plus chemotherapy</arm_group_label>
    <other_name>AVASTIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine combined with cisplatin chemotherapy</intervention_name>
    <description>Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.</description>
    <arm_group_label>Arm II: chemotherapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic documentation of primary lung carcinoma, non-squamous histology with EGFR&#xD;
             mutation Negative.&#xD;
&#xD;
          -  Stage IIIB/IV disease according to the 7th Edition of the American Joint Committee on&#xD;
             Cancer staging system&#xD;
&#xD;
          -  Not received radiotherapy, chemotherapy or other biological treatment&#xD;
&#xD;
          -  Measureable disease&#xD;
&#xD;
          -  Life expectancy of &gt;= 12 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 2, 500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and&#xD;
             serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 2.5 x&#xD;
             ULN in patients without liver or bone metastases; &lt; 5 x ULN in patients with liver or&#xD;
             bone metastases&#xD;
&#xD;
          -  Cockcroft-Gault calculated creatinine clearance of &gt;= 45 ml/min or creatinine =&lt; 1.5 x&#xD;
             ULN&#xD;
&#xD;
          -  Prothrombin time (PT) =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) =&lt; ULN&#xD;
&#xD;
          -  Urine dipstick proteinuria &lt; 2+ * Note: Patients discovered to have &gt;= 2 + proteinuria&#xD;
             on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must&#xD;
             demonstrate &lt; 1 g of protein in 24 hours&#xD;
&#xD;
          -  Negative pregnancy test done =&lt; 7 days prior to randomization, for women of&#xD;
             childbearing potential only&#xD;
&#xD;
          -  Provide informed written consent&#xD;
&#xD;
          -  Willing to return to Sichuan cancer hospital for follow-up&#xD;
&#xD;
          -  Willing to provide tissue and blood samples for correlative research purposes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a&#xD;
             predominant squamous component&#xD;
&#xD;
          -  Prior chemotherapy or treatment for metastatic non-small cell lung cancer&#xD;
&#xD;
          -  Immunocompromised patients (other than that related to the use of corticosteroids)&#xD;
             including patients known to be human immunodeficiency virus (HIV) positive, per MD&#xD;
             discretion&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Receiving any other investigational agent which would be considered as a treatment for&#xD;
             the primary neoplasm&#xD;
&#xD;
          -  Other active malignancy =&lt; 3 years prior to randomization; EXCEPTIONS: Non melanotic&#xD;
             skin cancer or carcinoma-in-situ of the cervix&#xD;
&#xD;
          -  History of myocardial infarction or other evidence of arterial thrombotic disease&#xD;
             (angina)&#xD;
&#xD;
          -  History of cerebral vascular accident (CVA) or transient ischemic attack (TIA) =&lt; 6&#xD;
             months prior to randomization&#xD;
&#xD;
          -  Ongoing or active infection, symptomatic congestive heart failure , cardiac&#xD;
             arrhythmia, psychiatric illness/social situations, or any other medical condition that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Inadequately controlled hypertension (systolic blood pressure of &gt; 150 mmHg or&#xD;
             diastolic pressure &gt; 100 mmHg on anti-hypertensive medications)&#xD;
&#xD;
          -  Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical&#xD;
             procedure, open biopsy, or significant traumatic injury =&lt; 28 days or core biopsy =&lt; 7&#xD;
             days prior to randomization&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intrabdominal abscess&#xD;
             =&lt; 6 months prior to randomization&#xD;
&#xD;
          -  History of hemoptysis &gt;= grade 2 (defined as bright red blood of at least 2.5 mL) =&lt; 3&#xD;
             months prior to randomization&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>juan li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan Cancer Hospital and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>juan li, doctor</last_name>
    <phone>+8613880276636</phone>
    <email>dr.lijuan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>rui shi, doctor</last_name>
    <phone>+8613880898008</phone>
    <email>shirui729@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>juan li, doctor</last_name>
      <phone>+8613880276636</phone>
      <email>dr.lijuan@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>rui shi, doctor</last_name>
      <phone>+8613880898008</phone>
      <email>shirui729@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>juan li, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yu dong, MD</last_name>
      <phone>+ 8618908178728</phone>
      <email>dongyu5610@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>June 15, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Cancer Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>Juan Li, MD</investigator_full_name>
    <investigator_title>attending physician</investigator_title>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>cisplatin</keyword>
  <keyword>EGFR wild-type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

